AHA: AstraZeneca’s Farxiga outcomes data looks even better in patients without diabetes
PHILADELPHIA––AstraZeneca’s SGLT2 med Farxiga has already stepped on the FDA fast track with trial data showing it could reduce heart failure risks in patients whether they have Type 2 diabetes or not. Turns out those “paradigm shifting” data show an even greater cardiovascular benefit for patients who don’t have diabetes than those who do—and this for a drug designed specifically to… Read More »